TABLE 1.
Top 10 intravenous cancer drugs by total provincial expenditure for 2006–2007 (per capita spending on each drug in brackets)
| BC | AB | SK | MB | ON | NB | NS | NL | |
|---|---|---|---|---|---|---|---|---|
| 1 | Trastuzumab (Herceptin) $18,898,738 ($4.59) |
Trastuzumab (Herceptin) $11,782,800 ($3.58) |
Trastuzumab (Herceptin) $4,087,800 ($4.22) |
Trastuzumab (Herceptin) $4,680,202 ($4.08) |
Trastuzumab (Herceptin) $51,328,968 ($4.22) |
Rituximab (Rituxan) $3,226,644 ($4.42) |
Trastuzumab (Herceptin) $3,240,000 ($3.55) |
Oxaliplatin (Eloxatin) $2,306,228 ($4.56) |
| 2 | Rituximab (Rituxan) $14,790,871 ($3.60) |
Rituximab (Rituxan) $7,926,078 ($2.41) |
Rituximab (Rituxan) $2,686,833 ($2.78) |
Rituximab (Rituxan) $3,466,541 ($3.02) |
Rituximab (Rituxan) $30,788,293 ($2.53) |
Trastuzumab (Herceptin) $2,347,910 ($3.22) |
Rituximab (Rituxan) $3,117,328 ($3.41) |
Trastuzumab (Herceptin) $2,019,600 ($4.00) |
| 3 | Oxaliplatin (Eloxatin) $8,468,959 ($2.06) |
Docetaxel (Taxotere) $5,029,310 ($1.53) |
Irinotecan (Camptosar) $1,030,772 ($1.06) |
Irinotecan (Camptosar) $1,946,533 ($1.69) |
Docetaxel (Taxotere) $16,839,367 ($1.38) |
Oxaliplatin (Eloxatin) $1,440,550 ($1.97) |
Docetaxel (Taxotere) $1,148,518 ($1.26) |
Bevacizumab (Avastin) $1,870,000 ($3.70) |
| 4 | Bevacizumab (Avastin) $5,228,970 ($1.27) |
Oxaliplatin (Eloxatin) $1,534,004 ($0.47) |
Docetaxel (Taxotere) $945,866 ($0.98) |
Docetaxel (Taxotere) $1,499,354 ($1.31) |
Irinotecan (Camptosar) $9,750,406 ($0.80) |
Docetaxel (Taxotere) $1,023,054 ($1.40) |
Irinotecan (Camptosar) $869,688 ($0.95) |
Docetaxel (Taxotere) $1,180,168 ($2.33) |
| 5 | Docetaxel (Taxotere) $4,893,147 ($1.19) |
Epirubicin (Pharmo-rubicin) $1,509,866 ($0.46) |
Oxaliplatin (Eloxatin) $871,186 ($0.90) |
Paciltaxel (Taxol) $1,080,120 ($0.94) |
Gemcitabine (Gemzar) $5,650,068 ($0.46) |
Irinotecan (Camptosar) $515,452 ($0.71) |
Oxaliplatin (Eloxatin) $787,733 ($0.86) |
Irinotecan (Camptosar) $585,680 ($1.16) |
| 6 | Gemcitabine (Gemzar) $2,958,344 ($0.72) |
Irinotecan (Camptosar) $1,485,473 ($0.45) |
Gemcitabine (Gemzar) $692,074 ($0.71) |
Goserelin (Zoladex) $604,706 ($0.53) |
Paclitaxel (Taxol) $4,419,378 ($0.36) |
Gemcitabine (Gemzar) $457,409 ($0.63) |
Gemcitabine (Gemzar) $755,321 ($0.83) |
Epirubicin (Pharmo-rubicin) $528,612 ($1.05) |
| 7 | Irinotecan (Camptosar) $2,235,550 ($0.54) |
Gemcitabine (Gemzar) $1,434,366 ($0.44) |
Paclitaxel (Taxol) $581,457 ($0.60) |
Gemcitabine (Gemzar) $579,406 ($0.50) |
Epirubicin (Pharmo-rubicin) $3,814,767 ($0.31) |
Bortezomib (Velcade) $435,690 ($0.60) |
Epirubicin (Pharmo-rubicin) $491,143 ($0.54) |
Rituximab1 (Rituxan) $315,356 ($0.62) |
| 8 | Paclitaxel (Taxol) $1,519,913 ($0.37) |
Bortezomib (Velcade) $1,144,368 ($0.35) |
Doxorubicin Liposome (Caelyx) $308,716 ($0.32) |
Leuprolide Acetate (Eligard) $536,874 ($0.47) |
Bortezomib (Velcade) $3,534,746 ($0.29) |
Cetuximab (Erbitux) $417,215 ($0.57) |
Doxorubicin Pegylated (Adriamycin) $456,244 ($0.50) |
Gemcitabine (Gemzar) $260,040 ($0.51) |
| 9 | Epirubicin (Pharmo-rubicin) $1,504,916 ($0.37) |
Doxorubicin Liposome (Doxil) $752,666 ($0.23) |
Epirubicin (Pharmo-rubicin) $268,184 ($0.28) |
Leuprolide Acetate (Eligard) $512,221 ($0.45) |
Pamidronate (Aredia) $3,423,262 ($0.28) |
Epirubicin (Pharmo-rubicin) $368,835 ($0.51) |
Paclitaxell (Taxol) $307,977 ($0.34) |
Doxorubicin Liposome (Caelyx) $150,000 ($0.30) |
| 10 | Bortezomib (Velcade) $1,175,440 ($0.29) |
Paclitaxell (Taxol) $712,595 ($0.22) |
Bortezomib (Velcade) $160,706 ($0.17) |
Bortezomib (Velcade) $335,034 ($0.29) |
Zolendronic Acid $2,585,663 ($0.21) |
Paclitaxel (Taxol) $251,173 ($0.34) |
Bortezomib (Velcade) $280,794 ($0.31) |
Cisplatin $128,720 ($0.25) |
Does not reflect total provincial expenditure.